Peter Attia· MD
it you know reduced cardiovascular death 38 it reduced uh heart failure renal failure i mean it was just an amazing thing and subsequently there's been oh a good seven mega trials now
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
it you know reduced cardiovascular death 38 it reduced uh heart failure renal failure i mean it was just an amazing thing and subsequently there's been oh a good seven mega trials now
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
and they're currently being studied frankly as just straight up longevity agents for exactly that reason
although the human data on the sglt2 inhibitors is also remarkable and i think that's yeah you know that's the sort of that's the theme here right is you have a great itp outcome and of course the human data are not for longevity but they're right again they suffer the the limitations of all human studies namely that they're being used in a subset of the population that might not be the subset of interest but you know the impact on kidney failure all-cause mortality heart failure is pretty impressive